pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its first quarter ended September 30, 2013.
“We made excellent progress this quarter in advancing our own pipeline of products, including our lead development product, Medidur™ for posterior uveitis, now in a Phase III trial, and in enhancing our capital with a $10.8 million public offering of our common stock,” said Dr. Paul Ashton, President and CEO of pSivida.
Help employers find you! Check out all the jobs and post your resume.
